Fragile X Study Finds Brain Wave Link in Humans, Mice

Researchers identify a non-invasive biomarker that could help advance treatment studies for the most common inherited form of autism.

Published on Feb. 21, 2026

Got story updates? Submit your updates here. ›

A team of MIT researchers, in collaboration with partners across the U.S. and U.K., has identified a brain wave biomarker that is shared between humans and mice with fragile X syndrome, the most common inherited form of autism. The researchers measured brain waves in human boys and men with and without fragile X, as well as in male mice with and without the genetic alteration that models the disorder. They found specific patterns of differences in low-frequency brain waves between typical and fragile X brains that were consistent across species and age ranges. The biomarker was also able to indicate the effects of a candidate treatment for fragile X called arbaclofen, which enhances inhibition in the brain.

Why it matters

Numerous potential treatments for neurological conditions like autism spectrum disorders have worked well in mice but then disappointed in humans. This new biomarker provides a non-invasive, objective readout of treatment efficacy that is shared in both species, which could help advance treatment studies for fragile X syndrome and potentially other brain disorders.

The details

The researchers measured EEG over the occipital lobe of humans and on the surface of the visual cortex of the mice, measuring power across the frequency spectrum. They found that in adult men and mice with fragile X, a peak in the power of low-frequency waves is shifted to a significantly slower frequency compared to neurotypical cases. In fragile X boys and juvenile mice, the power in that same peak is reduced. Further experiments showed that manipulating somatostatin interneurons, which help produce and shape brain wave patterns, specifically affected the lower-frequency subpeak that contained the fragile X biomarker. The researchers also demonstrated that the biomarker could indicate the effects of even single doses of the candidate treatment arbaclofen, which enhances GABA activity and has been shown to have a corrective effect.

  • The study was published on February 21, 2026.

The players

Sara Kornfeld-Sylla

A postdoc who led the research and developed the novel approach for analysis that enabled the discovery of the brain wave biomarker.

Mark Bear

A Picower Professor at MIT and faculty member in The Picower Institute for Learning and Memory and the Department of Brain and Cognitive Sciences, who supervised the research.

Fragile X Syndrome

The most common inherited form of autism.

Arbaclofen

A candidate treatment for fragile X syndrome that enhances inhibition in the brain by acting on GABA receptors.

Somatostatin Interneurons

A type of inhibitory neuron that helps produce and shape brain wave patterns, and was found to specifically affect the fragile X biomarker.

Got photos? Submit your photos here. ›

What they’re saying

“This research weaves together these different datasets and finds the connection between the brain wave activity that's happening in fragile X humans that is different from typically developed humans, and in the fragile X mouse model that is different than the 'wild-type' mice.”

— Sara Kornfeld-Sylla, Postdoc

“Because that is something we can measure in mice and humans minimally invasively, you can pose the question: If drug treatment X affects this signature in the mouse, at what dose does that same drug treatment change that same signature in a human? Then you have a mapping of physiological effects onto measures of behavior. And the mapping can go both ways.”

— Mark Bear, Picower Professor, MIT

What’s next

The researchers plan to further investigate the neural mechanisms underlying the fragile X brain wave biomarker and explore its potential applications for advancing treatment studies not only for fragile X syndrome, but for other brain disorders as well.

The takeaway

This study provides a promising new biomarker that can be used to directly compare brain activity between mice and humans with fragile X syndrome, which could significantly accelerate the development and testing of effective treatments for this common inherited form of autism.